Difference between revisions of "Part:BBa K2549021"
Line 12: | Line 12: | ||
<!-- Add more about the biology of this part here --> | <!-- Add more about the biology of this part here --> | ||
===Biology=== | ===Biology=== | ||
+ | =====Our characterization===== | ||
+ | [[File:bestNotch.jpg|none|400px|thumb|'''Flow cytometry results of SynNotch activation.''' surAg, surface antigens, which was surface-expressed CD19 for αCD19-SynNotch or surface-expressed EGFP for LaG-SynNotch, respectively. Without surAg, the EGFP (Y axis, driven by tTAA released after SynNotch activation) was low, and it went high after adding surAg. More details please visit http://2018.igem.org/Team:Fudan/Results and http://2018.igem.org/Team:Fudan/Optimization .]] | ||
+ | |||
+ | It is obvious that αCD19-mN1c-tTAA can be significantly activated by surface-expressed CD19. It also has the highest signal-to-noise ratio among all the SynNotch receptors that we submitted. Besides, it has a lower background activation ratio comparing to others. | ||
+ | |||
+ | |||
=====Clinical significance of anti-CD19===== | =====Clinical significance of anti-CD19===== | ||
Please refer to our basic [[Part:BBa_K2549005]] for more details. | Please refer to our basic [[Part:BBa_K2549005]] for more details. | ||
Line 22: | Line 28: | ||
Please refer to the original article for more details. | Please refer to the original article for more details. | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
<!-- Uncomment this to enable Functional Parameter display | <!-- Uncomment this to enable Functional Parameter display |
Revision as of 17:39, 17 October 2018
aCD19-mN1c-tTAA
This part is one of our SynNotch receptors, similar to the original published version[1]. It is our favorite. αCD19 (Part:BBa_K2549005) is used as the extracellular sensor module to receive the signal input from surface-expressed CD19. mN1c (Part:BBa_K2549006) is served as the transmembrane core domain of SynNotch, which is evident to have a low basal expression and a high activation efficiency. tTAA (Part:BBa_K2446057) is an improved tetracycline-controlled transactivator[2], which is cleaved after SynNotch activation and drives the expression of the amplifier. Besides, a CD8α signal peptide (Part:BBa_K2549044) and a Myc-tag (Part:BBa_K823036) are added to the N terminal of αCD19 (Part:BBa_K2549005) for membrane targeting and easy determination of surface expression.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 2493
- 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI site found at 534
Illegal SapI.rc site found at 1408
Biology
Our characterization
It is obvious that αCD19-mN1c-tTAA can be significantly activated by surface-expressed CD19. It also has the highest signal-to-noise ratio among all the SynNotch receptors that we submitted. Besides, it has a lower background activation ratio comparing to others.
Clinical significance of anti-CD19
Please refer to our basic Part:BBa_K2549005 for more details.
SynNotch receptors function well in Morsut L et al 2016
Please refer to the original article for more details.
References
- ↑ Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Morsut L, Roybal KT, Xiong X, ..., Thomson M, Lim WA. Cell, 2016 Feb;164(4):780-91 PMID: 26830878; DOI: 10.1016/j.cell.2016.01.012
- ↑ Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Urlinger S, Baron U, Thellmann M, ..., Bujard H, Hillen W. Proc Natl Acad Sci U S A, 2000 Jul;97(14):7963-8 PMID: 10859354